ClinicalTrials.gg
Enrolling by invitationNCT06975228TRUSTUpdated May 16, 2025

TReating Unhelpful Suspicious Thoughts in Adolescents (TRUST): a School-based Case Series

An interventional study of TRUST in Paranoia, sponsored by University of Sheffield. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 16 Years to 19 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by University of Sheffield · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
16 Years to 19 Years
Sex
All
01

Study summary

The goal of this acceptability and feasibility trial is to identify whether a six-session intervention for suspicious thoughts is feasible and acceptable to school-based adolescents.

The main research question is:

Is it feasible and acceptable to offer a brief imagery and values-based intervention for adolescents experiencing paranoia in schools?

Aims The primary aim of the current study is to identify whether a six-session brief intervention delivered in schools is feasible and acceptable to young people experiencing paranoia. Secondarily, it aims to identify preliminary outcomes of such an intervention on levels of paranoia, as measured by the Revised Green et al., Paranoid Thoughts Scale (R-GPTS).

Participants will be screened for paranoid thoughts and those eligible will be offered a six-session intervention. Participants will be asked to complete various measures prior to and following therapy.

02

Conditions studied

  • Paranoia

Browse trials for

Keywords

  • Paranoia
  • Adolescents
  • School
  • Feasibility
  • Acceptability
03

In context

Paranoid Disorders

20 studies on the registry are indexed under Paranoid Disorders; 7 are open to participants now.

This study's planned enrollment of 8 is below the median of 60 across 19 interventional studies indexed under Paranoid Disorders.

Browse Paranoid Disorders studies →

Lead sponsor

University of Sheffield is the lead sponsor of 75 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 16+
  • Attending participating school
  • Low risk
  • No current mental health support
  • Symptoms of paranoia i.e. scoring above 11 on R-GPTS part B subscales, equating to "moderately severe" paranoia and above

Exclusion criteria

Exclusion Criteria:

  • evidence of a primary alcohol or substance dependence issue at initial assessment;
  • developmental disability;
  • not fluent in English (due to questionnaire validity issues);
  • receiving another therapy at the same time;
  • moderate to high levels of risk
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    TRUST

    Six session psychological intervention focussing on imagery and values

    Behavioral: TRUST

Interventions

  • BehavioralTRUST

    Six-session psychological intervention focussing on values and imagery Session 1: Assessment, formulation and psychoeducation Session 2: Values and values-based goals Session 3-5: Harnessing imagery to pursue values and imagery focussed strategies to change negative beliefs about self and others Session 6: Review

06

What researchers measure

Primary outcomes

  1. Recruitment

    GREEN: \> 5 participants of target recruited AMBER = 3 to 4 of target recruited RED \< 2 of target recruited

    Time frame: Throughout course of study - 18 months

  2. Retention

    GREEN: 5 or more of participants providing end of therapy assessment outcome data AMBER: 3 to 4 participants providing end of therapy assessment outcome data RED: 2 or less of participants providing end of therapy assessment outcome data

    Time frame: Throughout course of study - 18 months

  3. Adherance

    GREEN= 5 or more participants attend at least 3 sessions of therapy AMBER\>= 3 to 4 participants attend at least 3 sessions of therapy RED: 2 or less of participants attend at least 3 sessions of therapy

    Time frame: Throughout course of study - 18 months

  4. Acceptability

    Acceptability of the therapy will be assessed via therapy process feedback questionnaire given to participants upon therapy completion or withdrawal and adverse effects of study participation questionnaire.

    Time frame: End of patient involvement

Secondary outcomes

  1. Revised Green et al., Paranoid Thoughts Scale (R-GPTS) Part B

    For screening of and assessing adolescents' paranoia, Revised Green et al., Paranoid Thoughts Scale (R-GPTS) will be used due to high reliability. The R-GPTS comprises of two subscales assessing for frequency of ideas of references (eight questions) and ideas of persecution (10 questions) on a five-point Likert scale. Part B will be used. "The R-GPTS score ranges are: average (Reference: 0-9; Persecution: 0-4); elevated (Reference: 10-15; Persecution: 5-10); moderately severe (Reference: 16-20; Persecution:11-17); severe (Reference: 21-24; Persecution: 18-27); and very severe (Reference: 25+; Persecution: 28+)". Clinical cut-offs on the persecution scales are 11 for persecutory ideation. Higher levels of RGPTs scores indicate higher difficulties.

    Time frame: Weekly sessions

  2. Comprehensive Assessment of Acceptance and Commitment Therapy processes for Youth (compACT-Y; Morey et al., 2024)

    The compACT-Y consists of 19-items scored on a six-point likert scale to assess psychological flexibility, with higher scores indicating higher flexibility. This includes the three factors of valued action, openness to experience and behavioural awareness, all linking to acceptance and commitment therapy (ACT) frameworks and methodology. This has been identified to be a valid and reliable measure for the use in young people.

    Time frame: Baseline assessment, post-therapy (following six sessions), 6 week follow-up

  3. Negative mental imagery questionnaire (MIQ-N)

    The MIQ-N consists of 16-items assessing for experiences of mental images. It has four sub-scales: intrusiveness, realness, controllability and beliefs about mental imagery. Participants are asked to rate how true each of the statements are to them on a seven-point Likert scale. Cronbach's alpha ranges from 0.84 - 0.90 when each of the subscales have been tested for reliability. The higher the score the higher the experience of negative mental images.

    Time frame: Baseline assessment, post-therapy (following six sessions), 6 week follow-up

  4. Brief Core Schema Scale (BCSS)

    The BCSS evaluates self and other beliefs using a 24-item scale, rating positive and negative self and other beliefs. Participants are asked to initially rate whether they hold the belief on yes/no and then rate the strength of the belief using a four-point Likert scale. Negative evaluations of self and others are suggested to be indicative of paranoia in the general population. The measure has good internal consistency for non-clinical samples (α = 0.74) and good retest-reliability for all subscales.

    Time frame: Baseline assessment, post-therapy (following six sessions), 6 week follow-up

  5. Work and Social Adjustment Scale - Youth (WSAS-Y)

    The WSAS-Y is a measure of functionality for young people in areas such as school, relationships and activities. It has five subscales and assesses severity of impairment using an eight-point scale, generating a total score out of 40, with greater scores indicating greater impairment. It has been suggested to have high internal consistency (α = 0.84) and reliability (r = 0.80).

    Time frame: Baseline assessment, post-therapy (following six sessions), 6 week follow-up

  6. Imagery characteristics

    The weekly imagery characteristics scale is a seven-item measure rating the characteristics of mental images including how real or pre-occupying they are. Participants are asked to rate each item on a 10-point scale from 'not at all' to 'extremely'.

    Time frame: Baseline assessment, post-therapy (following six sessions), 6 week follow-up

07

Study locations

1 site
  • Hanson School
    Bradford, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Apr 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 16, 2025
StartActual
May 2, 2025
Primary completionEst.
Apr 2026
CompletionEst.
May 2026
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06975228
Lead sponsor
University of Sheffield
Responsible party
Sponsor
First posted
May 16, 2025
Start date
May 2, 2025
Primary completion
Apr 2026 (estimated)
Completion
May 2026 (estimated)
Last update
May 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion